KORU Medical Systems Inc. Common Stock (DE)
KRMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KRMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KRMD
KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous drug delivery solutions, primarily for immunoglobulin therapy used in Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Key risk: Modest cash reserves
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials · 1 catalyst for KORU Medical Systems Inc. Common Stock (DE).
KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous drug delivery solutions, primarily for immunoglobulin therapy used in Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
- Cash & equivalents of $8.3M as of 2026-06-30 [sec].
- Total revenue of $12.0M and net income of $0.3M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $17.0M and total debt of $0.1M as of 2026-06-30 [sec].
- Inventory position was $4.5M at March 31, 2026, an increase of $0.8M from December 31, 2025, reflecting expected future demand [sec_mda · as of 2026-05-06].
- The company expects cash on hand, cash flows from operations, and its credit facility to be sufficient for at least the next twelve months [sec_mda · as of 2026-05-06].
What works
- Revenue grew 17.5% year-over-year to $9.6M in Q1 2025, indicating strong commercial traction [sec_mda · as of 2025-05-07].
- The company achieved profitability with net income of $0.3M in the latest reported period (six months ended 2026-06-30) [sec].
- Inventory build of $0.8M in Q1 2026 signals management's confidence in near-term demand [sec_mda · as of 2026-05-06].
- Low debt of $0.1M provides financial flexibility [sec].
What to weigh
- Cash reserves of $8.3M are modest relative to operating expenses, which were $28.6M in fiscal 2025 [sec_mda · as of 2026-03-12].
- The company's forward-looking statements caution about risks from inflation, tariffs, geopolitical conflicts, and customer ordering patterns [sec_mda · as of 2026-08-05].
- Longer-term strategic plans may require additional debt or equity financing, which could dilute shareholders [sec_mda · as of 2026-05-06].
- Dependence on the immunoglobulin market and new patient starts exposes the company to sector-specific demand fluctuations [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
The company develops and commercializes large-volume subcutaneous drug delivery solutions.
“The Company develops, manufactures and commercializes innovative patient-centric large volume subcutaneous solutions primarily for the subcutaneous drug delivery mark”
SEC MD&A · March 12, 2026
Revenue for Q1 2025 was $9.6 million, a 17.5% increase year-over-year.
“The Company ended the first quarter of 2025 with $9.6 million in net revenues, a 17.5% increase compared to $8.2 million”
SEC MD&A · May 7, 2025
Inventory at March 31, 2026 was $4.5 million, up $0.8 million from year-end 2025.
“Our inventory position was $4.5 million at March 31, 2026, which reflects an increase of $0.8 million from December 31, 2025, due to expected future demand from our customers.”
SEC MD&A · May 6, 2026
The company expects sufficient liquidity for at least the next twelve months.
“We expect that our cash on hand, cash flows from operations, and as needed, cash available under our credit facility, will be sufficient to meet our requirements at least through the next twelve months.”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2038-12-14 · Patent_Expiry · EMPAVELI — Patent/Exclusivity Expiry: EMPAVELI — Patent expiry for EMPAVELI could affect competitive landscape for subcutaneous drug delivery solutions.
Risks & what to watch (4)›
Key risks
- Modest cash reserves — Cash of $8.3M may be insufficient if operating losses continue; fiscal 2025 operating expenses were $28.6M [sec_mda · as of 2026-03-12].
- Macroeconomic and geopolitical risks — Inflation, tariffs, and geopolitical conflicts could impact costs and customer ordering patterns [sec_mda · as of 2026-08-05].
- Dependence on immunoglobulin market — Growth relies on new patient starts and expansion of the Ig market, which may not materialize as expected [sec_mda · as of 2026-08-05].
- Potential need for additional financing — Longer-term strategic plans may require drawing on credit facility, taking on debt, or issuing equity [sec_mda · as of 2026-05-06].
What to watch
- Quarterly revenue growth trajectory and ability to sustain profitability [sec].
- Cash burn rate and any need for additional financing [sec_mda · as of 2026-05-06].
- Updates on immunoglobulin market expansion and new patient starts [sec_mda · as of 2026-08-05].
- Regulatory developments and FDA compliance outcomes [sec_mda · as of 2026-08-05].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run KORU Medical Systems Inc. Common Stock (DE) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KORU Medical Systems Inc. Common Stock (DE) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.55 · 7% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~4489d
7 buys · 0 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$56.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,372,448 | $14.6M |
| blackrock, inc. | 2,371,826 | $10.2M |
| geode capital management, llc | 1,051,208 | $4.5M |
| meros investment management, lp | 760,451 | $3.3M |
| state street corp | 649,229 | $2.8M |
| russell investments group, ltd. | 423,419 | $1.8M |
| morgan stanley | 369,026 | $1.6M |
| northern trust corp | 322,252 | $1.4M |
| vanguard fiduciary trust co | 306,453 | $1.3M |
| vanguard portfolio management llc | 255,455 | $1.1M |
Showing top 10 of 86 institutional holders of KORU Medical Systems Inc. Common Stock (DE). Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 1.9%
- Days to cover
- 4.7
- Shares short
- 736,923
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KRMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for KORU Medical Systems Inc. Common Stock (DE)?
KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous drug delivery solutions, primarily for immunoglobulin therapy used in Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
What is KORU Medical Systems Inc. Common Stock (DE)'s next catalyst?
KORU Medical Systems Inc. Common Stock (DE)'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: EMPAVELI" — expected December 14, 2038.
Who is the CEO of KORU Medical Systems Inc. Common Stock (DE)?
Mr. Adam Kalbermatten is the chief executive officer of KORU Medical Systems Inc. Common Stock (DE) (KRMD).
Where is KORU Medical Systems Inc. Common Stock (DE) headquartered?
KORU Medical Systems Inc. Common Stock (DE) (KRMD) is headquartered in Mahwah, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.